Ignite Creation Date:
2025-12-24 @ 9:54 PM
Ignite Modification Date:
2026-03-10 @ 6:18 PM
Study NCT ID:
NCT02511132
Status:
COMPLETED
Last Update Posted:
2022-12-22
First Post:
2015-07-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Sponsor:
Gradalis, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CL-PTL-121
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None